Amerigen and Biophore Collaborate on Penicillamine Generics

LYNDHURST, N.J., Oct. 24, 2017 /PRNewswire/ -- Amerigen Pharmaceuticals Limited ("Amerigen") and Biophore India Pharmaceuticals Pvt Ltd. ("Biophore") today announced that they are collaborating to bring a generic version of Valeant's Cuprimine and other penicillamine based generic products to the U.S. market using active pharmaceutical ingredient supplied by Biophore from India. Amerigen has already filed an Abbreviated New Drug Application ("ANDA") with the U.S Food & Drug Administration ("FDA") for potentially the first generic equivalent of Cuprimine, which has been accepted for filing and is now under FDA review. John Lowry, Amerigen's President & CEO, stated that "After the well publicized price increases for Cuprimine over the last several years, Amerigen looks forward to securing FDA approval for its pending ANDA and bringing a lower cost version of this important medication to U.S. patients."

About Amerigen
Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province. The group has products on the market currently in both the US and China plus an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese CFDA. Amerigen's focus is orally delivered products that are potential first generics, challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.

Contact Information: Michelle Valsera. Telephone (732) 993-9821 or [email protected]

SOURCE Amerigen Pharmaceuticals